Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 3Phase EARLY_PHASE1 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 9OTHER 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Gastrointestinal 1Dermatologic 1

Conditions

Uveal Melanoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Melanoma 1Liver Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER × oblimersen × Clear all
NCT00049374 2019-10-17

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

University of Maryland, Baltimore

Phase 2 Completed
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00047229 2017-11-08

Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

University Health Network, Toronto

Phase 2 Completed
27 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01200342 2016-02-11

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

M.D. Anderson Cancer Center

Phase 2 Terminated
7 enrolled 3 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡